Wake Forest University

The State University of New York

Emory University

R.j. Reynolds Tobacco Company

Children's Healthcare of Atlanta, Inc.

Hauptman-Woodward Medical Research Institute, Inc.

Huw M Davies

Steven R Childers

Elie Saikali

William Scott Caldwell

Patrick Michael Lippiello

Haian Fu

Yuhong Du

Spandan Chennamadhavuni

Candela Manfredi

Thomas J Martin

Eric Sorscher

Norman Kong

Jeong Hong

Barbara Bennett

Dabashis Ghosh

Zhi Ren

Andras Rab

Daniel Morton

Xun Yang

Debashis Ghosh

This disclosure relates to compounds that are cystic fibrosis transmembrane conductance regulator (CFTR) modulators and pharmaceutical compositions containing the same. In certain embodiments, this disclosure relates to methods of managing a CFTR related disease or condition or respiratory distress comprising administering an effective amount of a CFTR modulator disclosed herein to a subject in need thereof.

Cystic fibrosis transmembrane conductance regulator (CFTR) modulators, pharmaceutical compositions, and uses thereof

The disclosure relates to novel C4 and C6 substituted androst-4-ene diones as well as andros-1,4-diene diones and derivatives thereof, their process of preparation, pharmaceutical compounds containing them, and the use of said compounds for the treatment of hormone-related disorders in mammals. This includes hormone-dependent cancers, particularly those caused by elevated levels of estrogen and its intermediates. These compounds can also be used in the treatment of other hormone-related disorders, including benign prostatic hyperplasia, cardiovascular disease, and neurodegenerative disorders.

Substituted androst-4-ene diones

Biologically active derivatives of the tropane ring system are provided which selectively bind either to the 5-HT or DA reuptake site, leading to compounds which have use for the treatment of clinical depression, attention deficit disorder, obesity and cocaine addiction.

Tropane derivatives with selective binding to the serotonin reuptake

Selective blockade of DA and 5-HT uptake sites with 3-aryltropane derivatives.

Process for blocking 5-HT and dopamine uptake with biologically active

A process of enantioselective synthesis of seven-membered carbocycles in the presence of di-rhodium(II) tetracarboxylate catalysts.

Enantioselective synthesis of seven-membered carbocycles and tropanes

Preparation of biologically active tropane derivatives of novel configurations. The compounds are prepared by decomposing vinyldiazomethanes in the presence of pyrroles to provide a bicyclic ring containing the basic tropane ring system which is then reacted with an aryl Grignard reagent in the presence of a copper (I) or (II) salt to provide 3-aryl-tropane derivatives.

2 step process for preparing biologically active tropane derivatives and

Novel tropane ring system compounds useful for treatment of neurological disorders and for synthetic starting materials for production of cocaine analogs.

Compounds for treatment of neurodegenerative diseases

Preparation of biologically active tropane derivatives of novel configurations. The compounds are prepared by decomposing vinyldiazomethanes in the presence of pyrroles to provide a bicyclic ring containing the basic tropane ring system which is then reacted with an aryl Grignard reagent in the presence of a copper (I) or (II) salt to provide 3-aryltropane derivatives.

Biologically active tropane derivatives

Patients suffering from neurodegenerative diseases are treated by administering an effective amount of a ferruginine compound or a anhydroecgonine compound.

Growing community of inventors

Clemmons, NC, United States of America

Huw M Davies